GeneOne Life Science, Inc. (KRX: 011000)

GeneOne Life Science Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,064	9,111	13,261	22,310	62,432	16,922
Short-Term Investments	996.46	406.6	32,342	85,094	28,086	555.13
Trading Asset Securities	1,441	470.79	-	-	-	-
Cash & Short-Term Investments	4,501	9,988	45,603	107,404	90,518	17,477
Cash Growth	-49.35%	-78.10%	-57.54%	18.65%	417.94%	-22.08%
Accounts Receivable	6,467	6,624	8,980	7,438	7,408	9,122
Other Receivables	934.56	948.44	1,598	1,975	374.05	296.74
Receivables	7,481	7,652	10,659	10,091	8,401	9,576
Inventory	16,500	14,897	14,864	10,688	8,299	8,746
Prepaid Expenses	1,323	1,225	1,145	706.46	1,226	619.64
Other Current Assets	459.52	811	793.08	5,744	315.08	178.45
Total Current Assets	30,266	34,573	73,063	134,633	108,760	36,596
Property, Plant & Equipment	115,783	111,399	144,369	110,382	22,427	10,004
Long-Term Investments	70.83	50.39	147.49	437.33	710.58	284.17
Other Intangible Assets	341.89	385.99	563.91	643.1	683.11	578.87
Long-Term Deferred Tax Assets	14.31	13.28	36.42	14.24	154.29	186.03
Other Long-Term Assets	4,129	4,586	4,687	4,735	3,750	3,338
Total Assets	150,604	151,008	222,867	250,857	136,571	51,152
Accounts Payable	-	10,066	7,493	17,531	6,881	2,294
Accrued Expenses	1,048	1,971	2,327	1,173	931.56	929.71
Short-Term Debt	2,363	2,405	12,246	9,754	15,634	11,267
Current Portion of Leases	-	2,396	1,911	1,543	1,337	1,207
Other Current Liabilities	20,775	6,029	9,858	4,758	11,920	6,954
Total Current Liabilities	24,186	22,867	33,836	34,759	36,705	22,653
Long-Term Debt	11,308	6,273	-	-	-	-
Long-Term Leases	5,059	6,085	5,509	7,103	794.09	2,013
Long-Term Deferred Tax Liabilities	349.06	323.98	457.33	144.32	-	-
Other Long-Term Liabilities	2,164	1,872	1,594	1,524	473.64	333.67
Total Liabilities	45,168	39,518	41,395	44,350	38,062	27,092
Common Stock	80,039	78,474	77,752	77,479	44,771	21,926
Additional Paid-In Capital	217,579	215,555	214,299	209,871	117,319	45,251
Retained Earnings	-238,517	-216,231	-137,155	-98,241	-81,567	-62,276
Treasury Stock	-2,955	-2,955	-2,955	-2,955	-2,371	-2,371
Comprehensive Income & Other	49,290	36,647	29,531	20,353	20,357	21,530
Shareholders' Equity	105,436	111,489	181,471	206,507	98,509	24,060
Total Liabilities & Equity	150,604	151,008	222,867	250,857	136,571	51,152
Total Debt	18,730	17,160	19,666	18,400	17,766	14,487
Net Cash (Debt)	-14,229	-7,171	25,937	89,004	72,752	2,990
Net Cash Growth	-	-	-70.86%	22.34%	2333.27%	-70.23%
Net Cash Per Share	-181.22	-92.24	334.73	1198.84	1205.09	93.12
Filing Date Shares Outstanding	79.83	78.26	77.54	77.27	66.9	32.63
Total Common Shares Outstanding	79.83	78.26	77.54	77.27	66.9	32.63
Working Capital	6,079	11,705	39,227	99,875	72,055	13,943
Book Value Per Share	1320.77	1424.52	2340.29	2672.55	1472.58	737.41
Tangible Book Value	105,095	111,103	180,907	205,864	97,826	23,481
Tangible Book Value Per Share	1316.49	1419.59	2333.02	2664.23	1462.37	719.67
Land	3,460	3,139	4,081	3,817	3,503	-
Buildings	71,175	63,374	1,403	1,331	1,328	1,337
Machinery	52,395	48,599	15,199	11,775	9,776	8,988
Construction In Progress	-	-	104,661	78,283	11,489	-
Leasehold Improvements	15,512	14,867	13,139	12,124	6,739	6,330

Source: S&P Capital IQ. Standard template. Financial Sources.